Nabriva Therapeutics AG Company Profile (NASDAQ:NBRV)

About Nabriva Therapeutics AG (NASDAQ:NBRV)

Nabriva Therapeutics AG logoNabriva Therapeutics plc is a clinical stage biopharmaceutical company. The Company is engaged in engaged in the research and development of novel anti-infectives to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The Company's medicinal chemistry has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations of its lead product candidate, lefamulin. Lefamulin is a novel semi-synthetic pleuromutilin antibiotic with the potential to be the first-in-class available for systemic administration in humans. Lefamulin is being evaluated in two global, registrational Phase III clinical trials in patients with moderate to severe community-acquired bacterial pneumonia (CABP).It seeks to further pursue development of lefamulin for additional indications, including the treatment of acute bacterial skin and skin structure infections (ABSSSI), and is developing a formulation of lefamulin appropriate for pediatric use.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research - NEC
  • Sub-Industry: N/A
  • Symbol: NASDAQ:NBRV
  • CUSIP: N/A
  • Web: www.nabriva.com
Capitalization:
  • Market Cap: $237.52 million
  • Outstanding Shares: 26,838,000
Average Prices:
  • 50 Day Moving Avg: $10.19
  • 200 Day Moving Avg: $10.38
  • 52 Week Range: $3.52 - $12.75
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.25
  • P/E Growth: -0.06
Sales & Book Value:
  • Annual Revenue: $6.01 million
  • Price / Sales: 39.52
  • Book Value: $1.85 per share
  • Price / Book: 4.78
Profitability:
  • EBIDTA: ($59,300,000.00)
  • Return on Equity: -90.54%
  • Return on Assets: -72.82%
Debt:
  • Current Ratio: 3.77%
  • Quick Ratio: 3.77%
Misc:
  • Average Volume: 20,077 shs.
  • Beta: 1.64
  • Short Ratio: 3.94
 

Frequently Asked Questions for Nabriva Therapeutics AG (NASDAQ:NBRV)

What is Nabriva Therapeutics AG's stock symbol?

Nabriva Therapeutics AG trades on the NASDAQ under the ticker symbol "NBRV."

How were Nabriva Therapeutics AG's earnings last quarter?

Nabriva Therapeutics AG (NASDAQ:NBRV) released its quarterly earnings results on Monday, August, 7th. The company reported ($0.54) EPS for the quarter, beating the Zacks' consensus estimate of ($5.83) by $5.29. The firm earned $1.05 million during the quarter, compared to the consensus estimate of $1.34 million. View Nabriva Therapeutics AG's Earnings History.

When will Nabriva Therapeutics AG make its next earnings announcement?

Nabriva Therapeutics AG is scheduled to release their next quarterly earnings announcement on Wednesday, November, 15th 2017. View Earnings Estimates for Nabriva Therapeutics AG.

Where is Nabriva Therapeutics AG's stock going? Where will Nabriva Therapeutics AG's stock price be in 2017?

6 analysts have issued 12 month price objectives for Nabriva Therapeutics AG's shares. Their forecasts range from $13.00 to $22.00. On average, they expect Nabriva Therapeutics AG's share price to reach $16.00 in the next twelve months. View Analyst Ratings for Nabriva Therapeutics AG.

What are analysts saying about Nabriva Therapeutics AG stock?

Here are some recent quotes from research analysts about Nabriva Therapeutics AG stock:

  • 1. According to Zacks Investment Research, "Nabriva Therapeutics AG is a biopharmaceutical company. The Company is involved in the research and development of novel anti-infective agents to treat serious infections, which focus on the pleuromutilin class of antibiotics. Its product candidate consists of BC-3781, developed for the treatment of serious skin infections and bacterial pneumonia caused by MRSA and other drug resistant bacteria; BC-7013, a topical pleuromutilin antibiotic which are in different clinical trial. Nabriva Therapeutics AG is based in Vienna, Austria. " (8/15/2017)
  • 2. Needham & Company LLC analysts commented, "Nabriva reported 4Q16 financial results last week. Top- line results from LEAP1, first of two ongoing Phase 3 trials of lefamulin in Community Pneumonia (CABP), are expected 3Q17. This trial is evaluating both IV and oral formulations. Top-line results from LEAP2, which is evaluating only oral formulation, are expected 1Q18 (was 4Q17). We are favorably inclined based on Phase 2 IV skin infection trial, Phase 1 oral PK trial, and Phase 1 lung trial. We believe Solithera (Cempra) is unlikely to reach market, creating a vacuum in outpatient CABP space. If lefamulin is found to have particularly safe profile, drug may ultimately be useful not only in hospital setting for severe CABP , but also in much broader outpatient setting." (3/27/2017)
  • 3. Wedbush analysts commented, "Nabriva recently reported that LEAP-1 has achieved 60% of its enrollment target, remaining on track to report data from both Ph 3 studies in 2H17 ' we believe both these readouts will be positive. In addition, we believe lefamulin's product profile possesses the key attributes required to take advantage of the commercial opportunity in CABP." (1/31/2017)

Who are some of Nabriva Therapeutics AG's key competitors?

Who are Nabriva Therapeutics AG's key executives?

Nabriva Therapeutics AG's management team includes the folowing people:

  • Daniel D. Burgess, Independent Chairman of the Supervisory Board
  • Colin Broom M.D., Chief Executive Officer
  • Gary L. Sender, Chief Financial Officer
  • William Q. Sargent, Vice President - Commercial Strategy and Investor Relations
  • Robert L. Crotty, General Counsel
  • Steven P. Gelone, Chief Development Officer
  • Elyse G. Seltzer M.D., Chief Medical Officer
  • Mark H.N. Corrigan M.D., Independent Member of the Supervisory Board
  • Chau Quang Khuong, Independent Member of the Supervisory Board
  • Charles A. Rowland Jr., Independent Member of the Supervisory Board

Who owns Nabriva Therapeutics AG stock?

Nabriva Therapeutics AG's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Vivo Capital LLC (147.80%), Omega Fund Management LLC (4.25%), Almanack Investment Partners LLC. (33.34%), Hillhouse Capital Management Ltd. (2.56%), Franklin Resources Inc. (12.86%) and EcoR1 Capital LLC (0.99%). Company insiders that own Nabriva Therapeutics AG stock include George Harrison Talbot and Hbm Healthcare Investments (Ca. View Institutional Ownership Trends for Nabriva Therapeutics AG.

Who sold Nabriva Therapeutics AG stock? Who is selling Nabriva Therapeutics AG stock?

Nabriva Therapeutics AG's stock was sold by a variety of institutional investors in the last quarter, including Tekla Capital Management LLC, Omega Fund Management LLC and Hillhouse Capital Management Ltd.. Company insiders that have sold Nabriva Therapeutics AG stock in the last year include George Harrison Talbot and Hbm Healthcare Investments (Ca. View Insider Buying and Selling for Nabriva Therapeutics AG.

Who bought Nabriva Therapeutics AG stock? Who is buying Nabriva Therapeutics AG stock?

Nabriva Therapeutics AG's stock was purchased by a variety of institutional investors in the last quarter, including Almanack Investment Partners LLC., Royal Bank of Canada and Nationwide Fund Advisors. View Insider Buying and Selling for Nabriva Therapeutics AG.

How do I buy Nabriva Therapeutics AG stock?

Shares of Nabriva Therapeutics AG can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Nabriva Therapeutics AG's stock price today?

One share of Nabriva Therapeutics AG stock can currently be purchased for approximately $8.85.


MarketBeat Community Rating for Nabriva Therapeutics AG (NASDAQ NBRV)
Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  109 (Vote Outperform)
Underperform Votes:  56 (Vote Underperform)
Total Votes:  165
MarketBeat's community ratings are surveys of what our community members think about Nabriva Therapeutics AG and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Nabriva Therapeutics AG (NASDAQ:NBRV) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 6 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $16.00 (80.79% upside)

Analysts' Ratings History for Nabriva Therapeutics AG (NASDAQ:NBRV)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/11/2017Cantor FitzgeraldSet Price TargetBuy$16.00MediumView Rating Details
6/30/2017HC WainwrightReiterated RatingBuy$16.00MediumView Rating Details
5/15/2017WedbushReiterated RatingOutperform$13.00HighView Rating Details
3/27/2017Needham & Company LLCReiterated RatingBuy$15.00LowView Rating Details
12/20/2016Royal Bank Of CanadaSet Price TargetBuy$22.00N/AView Rating Details
10/27/2016Leerink SwannReiterated RatingOutperform$14.00N/AView Rating Details
1/27/2016GabelliInitiated CoverageBuy$14.00N/AView Rating Details
(Data available from 8/21/2015 forward)

Earnings

Earnings History for Nabriva Therapeutics AG (NASDAQ:NBRV)
Earnings by Quarter for Nabriva Therapeutics AG (NASDAQ:NBRV)
Earnings History by Quarter for Nabriva Therapeutics AG (NASDAQ NBRV)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/15/2017        
8/7/20176/30/2017($5.83)($0.54)$1.34 million$1.05 millionViewN/AView Earnings Details
11/16/2016Q3($0.55)($0.66)$1.60 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Nabriva Therapeutics AG (NASDAQ:NBRV)
2017 EPS Consensus Estimate: ($2.22)
2018 EPS Consensus Estimate: ($1.83)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.60)($0.55)($0.58)
Q2 20172($0.60)($0.56)($0.58)
Q3 20172($0.58)($0.58)($0.58)
Q4 20172($0.50)($0.46)($0.48)
Q1 20181($0.46)($0.46)($0.46)
Q2 20181($0.45)($0.45)($0.45)
Q3 20181($0.46)($0.46)($0.46)
Q4 20181($0.46)($0.46)($0.46)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Nabriva Therapeutics AG (NASDAQ:NBRV)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Nabriva Therapeutics AG (NASDAQ:NBRV)
Institutional Ownership Percentage: 56.65%
Insider Trades by Quarter for Nabriva Therapeutics AG (NASDAQ:NBRV)
Institutional Ownership by Quarter for Nabriva Therapeutics AG (NASDAQ:NBRV)
Insider Trades by Quarter for Nabriva Therapeutics AG (NASDAQ:NBRV)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/8/2017Hbm Healthcare Investments (CaMajor ShareholderSell19,803$10.50$207,931.50View SEC Filing  
8/7/2017Hbm Healthcare Investments (CaMajor ShareholderSell17,790$10.50$186,795.00View SEC Filing  
7/28/2017Hbm Healthcare Investments (CaMajor ShareholderSell6,585$10.51$69,208.35View SEC Filing  
7/24/2017Hbm Healthcare Investments (CaMajor ShareholderSell160$10.50$1,680.00View SEC Filing  
7/20/2017Hbm Healthcare Investments (CaMajor ShareholderSell44,231$10.50$464,425.50View SEC Filing  
7/18/2017Hbm Healthcare Investments (CaMajor ShareholderSell69,854$10.51$734,165.54View SEC Filing  
7/13/2017Hbm Healthcare Investments (CaMajor ShareholderSell57,175$10.53$602,052.75View SEC Filing  
7/7/2017Hbm Healthcare Investments (CaMajor ShareholderSell2,695$10.52$28,351.40View SEC Filing  
7/3/2017Hbm Healthcare Investments (CaMajor ShareholderSell13,127$10.94$143,609.38View SEC Filing  
6/30/2017Hbm Healthcare Investments (CaMajor ShareholderSell1,775$10.94$19,418.50View SEC Filing  
6/29/2017Hbm Healthcare Investments (CaMajor ShareholderSell8,558$10.96$93,795.68View SEC Filing  
6/19/2017George Harrison TalbotDirectorSell170$93.18$15,840.60View SEC Filing  
5/30/2017George Harrison TalbotDirectorSell210$101.26$21,264.60View SEC Filing  
5/25/2017George Harrison TalbotDirectorSell325$100.56$32,682.00View SEC Filing  
5/16/2017George Harrison TalbotDirectorSell200$102.44$20,488.00View SEC Filing  
5/15/2017George Harrison TalbotDirectorSell50$101.50$5,075.00View SEC Filing  
4/28/2017Hbm Healthcare Investments (CaMajor ShareholderSell15,939$11.02$175,647.78View SEC Filing  
4/21/2017Hbm Healthcare Investments (CaMajor ShareholderSell2,622$11.04$28,946.88View SEC Filing  
4/20/2017Hbm Healthcare Investments (CaMajor ShareholderSell23,932$11.11$265,884.52View SEC Filing  
4/13/2017Hbm Healthcare Investments (CaMajor ShareholderSell32,831$11.24$369,020.44View SEC Filing  
4/10/2017Hbm Healthcare Investments (CaMajor ShareholderSell90,594$10.96$992,910.24View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Nabriva Therapeutics AG (NASDAQ:NBRV)
Latest Headlines for Nabriva Therapeutics AG (NASDAQ:NBRV)
Source:
DateHeadline
americanbankingnews.com logoQ3 2017 Earnings Estimate for Nabriva Therapeutics AG (NASDAQ:NBRV) Issued By Wedbush
www.americanbankingnews.com - August 14 at 2:30 AM
americanbankingnews.com logoCantor Fitzgerald Comments on Nabriva Therapeutics AG's FY2017 Earnings (NASDAQ:NBRV)
www.americanbankingnews.com - August 10 at 10:42 AM
americanbankingnews.com logoNabriva Therapeutics AG (NASDAQ:NBRV) Major Shareholder Sells $186,795.00 in Stock
www.americanbankingnews.com - August 9 at 10:22 PM
americanbankingnews.com logoNabriva Therapeutics AG (NASDAQ:NBRV) Major Shareholder Hbm Healthcare Investments (Ca Sells 19,803 Shares
www.americanbankingnews.com - August 9 at 10:20 PM
americanbankingnews.com logoQ3 2017 Earnings Estimate for Nabriva Therapeutics AG Issued By Leerink Swann (NASDAQ:NBRV)
www.americanbankingnews.com - August 9 at 7:46 AM
americanbankingnews.com logoNabriva Therapeutics AG (NBRV) Releases Quarterly Earnings Results, Beats Expectations By $5.29 EPS
www.americanbankingnews.com - August 8 at 1:36 PM
streetinsider.com logoForm 10-Q Nabriva Therapeutics For: Jun 30
www.streetinsider.com - August 8 at 3:54 AM
finance.yahoo.com logoNabriva Therapeutics Reports Second Quarter 2017 Financial Results and Recent Corporate Highlights
finance.yahoo.com - August 7 at 10:52 PM
americanbankingnews.com logoZacks: Analysts Anticipate Nabriva Therapeutics AG (NBRV) Will Post Quarterly Sales of $1.34 Million
www.americanbankingnews.com - August 6 at 7:54 AM
americanbankingnews.com logoZacks: Brokerages Expect Nabriva Therapeutics AG (NBRV) to Post -$0.57 EPS
www.americanbankingnews.com - August 4 at 12:28 PM
finance.yahoo.com logoNabriva Therapeutics to Present at the 2017 Wedbush PacGrow Healthcare Conference
finance.yahoo.com - August 3 at 6:11 AM
americanbankingnews.com logoNabriva Therapeutics AG (NBRV) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - August 2 at 12:58 AM
americanbankingnews.com logoHbm Healthcare Investments (Ca Sells 6,585 Shares of Nabriva Therapeutics AG (NBRV) Stock
www.americanbankingnews.com - August 1 at 10:14 PM
americanbankingnews.com logoNabriva Therapeutics AG (NASDAQ:NBRV) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - August 1 at 8:42 AM
americanbankingnews.com logoNabriva Therapeutics AG (NBRV) Major Shareholder Sells $464,425.50 in Stock
www.americanbankingnews.com - July 22 at 7:22 AM
americanbankingnews.com logoHbm Healthcare Investments (Ca Sells 69,854 Shares of Nabriva Therapeutics AG (NASDAQ:NBRV) Stock
www.americanbankingnews.com - July 18 at 10:29 PM
americanbankingnews.com logoNabriva Therapeutics AG (NASDAQ:NBRV) Expected to Announce Quarterly Sales of $1.34 Million
www.americanbankingnews.com - July 15 at 9:42 AM
americanbankingnews.com logoNabriva Therapeutics AG (NASDAQ:NBRV) Major Shareholder Hbm Healthcare Investments (Ca Sells 57,175 Shares
www.americanbankingnews.com - July 13 at 10:53 PM
americanbankingnews.com logoZacks: Analysts Anticipate Nabriva Therapeutics AG (NASDAQ:NBRV) to Announce -$0.57 Earnings Per Share
www.americanbankingnews.com - July 13 at 8:28 AM
americanbankingnews.com logoNabriva Therapeutics AG (NBRV) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - July 13 at 12:50 AM
finance.yahoo.com logoNabriva Therapeutics Appoints Francesco Maria Lavino as Chief Commercial Officer
finance.yahoo.com - July 12 at 6:13 AM
americanbankingnews.com logoNabriva Therapeutics AG (NASDAQ:NBRV) Major Shareholder Sells $28,351.40 in Stock
www.americanbankingnews.com - July 7 at 10:43 PM
americanbankingnews.com logoNabriva Therapeutics AG (NBRV) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - July 7 at 8:54 AM
americanbankingnews.com logoInsider Selling: Nabriva Therapeutics AG (NBRV) Major Shareholder Sells 13,127 Shares of Stock
www.americanbankingnews.com - July 5 at 10:44 PM
americanbankingnews.com logoNabriva Therapeutics AG (NASDAQ:NBRV) Major Shareholder Sells $19,418.50 in Stock
www.americanbankingnews.com - July 5 at 10:44 PM
americanbankingnews.com logoNabriva Therapeutics AG - (NBRV) Rating Reiterated by HC Wainwright
www.americanbankingnews.com - June 30 at 2:17 PM
americanbankingnews.com logoNabriva Therapeutics AG (NBRV) Major Shareholder Sells $93,795.68 in Stock
www.americanbankingnews.com - June 29 at 10:28 PM
finance.yahoo.com logoNabriva Therapeutics plc Successfully Concludes Tender Offer for Outstanding Common Shares of Nabriva Therapeutics AG and Outstanding American Depositary Shares of Nabriva Therapeutics AG
finance.yahoo.com - June 26 at 8:51 AM
finance.yahoo.com logoNabriva Therapeutics Appoints Carrie Bourdow and Colin Broom to the Board
finance.yahoo.com - June 26 at 8:51 AM
americanbankingnews.com logoNabriva Therapeutics AG (NBRV) Upgraded at ValuEngine
www.americanbankingnews.com - June 24 at 9:38 PM
americanbankingnews.com logoCantor Fitzgerald Initiates Coverage on Nabriva Therapeutics AG (NBRV)
www.americanbankingnews.com - June 22 at 9:16 PM
americanbankingnews.com logoGeorge Harrison Talbot Sells 170 Shares of Nabriva Therapeutics AG (NBRV) Stock
www.americanbankingnews.com - June 19 at 8:22 PM
americanbankingnews.com logoZacks: Brokerages Expect Nabriva Therapeutics AG (NBRV) to Announce -$0.57 EPS
www.americanbankingnews.com - June 19 at 7:48 AM
americanbankingnews.com logoNabriva Therapeutics AG (NBRV) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - June 12 at 9:46 AM
americanbankingnews.com logoNabriva Therapeutics AG - (NBRV) Director Sells $21,264.60 in Stock
www.americanbankingnews.com - June 6 at 5:42 PM
americanbankingnews.com logoNabriva Therapeutics AG - (NBRV) PT Set at $16.00 by Cantor Fitzgerald
www.americanbankingnews.com - June 5 at 2:26 PM
finance.yahoo.com logoNabriva Therapeutics Announces Webcast of Analyst & Investor Day on June 19, 2017
finance.yahoo.com - June 5 at 9:00 AM
americanbankingnews.com logoGeorge Harrison Talbot Sells 210 Shares of Nabriva Therapeutics AG - (NBRV) Stock
www.americanbankingnews.com - June 1 at 10:46 PM
americanbankingnews.com logoZacks Investment Research Upgrades Nabriva Therapeutics AG - (NBRV) to "Buy"
www.americanbankingnews.com - May 27 at 7:46 AM
americanbankingnews.com logoGeorge Harrison Talbot Sells 325 Shares of Nabriva Therapeutics AG - (NBRV) Stock
www.americanbankingnews.com - May 25 at 10:20 PM
finance.yahoo.com logoNabriva Commences Previously Announced Tender Offer Related to the Proposed Redomicile of its Holding Company from Austria to Ireland
finance.yahoo.com - May 23 at 10:17 AM
americanbankingnews.com logoInsider Selling: Nabriva Therapeutics AG - (NBRV) Director Sells 200 Shares of Stock
www.americanbankingnews.com - May 17 at 8:34 PM
americanbankingnews.com logoQ2 2017 Earnings Estimate for Nabriva Therapeutics AG - Issued By Wedbush (NBRV)
www.americanbankingnews.com - May 17 at 7:46 AM
americanbankingnews.com logoNabriva Therapeutics AG - Forecasted to Earn Q1 2018 Earnings of ($0.43) Per Share (NBRV)
www.americanbankingnews.com - May 16 at 10:48 AM
americanbankingnews.com logoNabriva Therapeutics AG - (NBRV) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - May 16 at 8:06 AM
americanbankingnews.com logoNabriva Therapeutics AG -'s (NBRV) Outperform Rating Reiterated at Wedbush
www.americanbankingnews.com - May 15 at 4:28 PM
americanbankingnews.com logoQ2 2017 Earnings Estimate for Nabriva Therapeutics AG - (NBRV) Issued By Leerink Swann
www.americanbankingnews.com - May 15 at 7:40 AM
americanbankingnews.com logoNabriva Therapeutics AG - (NBRV) Given a $16.00 Price Target at Cantor Fitzgerald
www.americanbankingnews.com - May 13 at 5:50 PM
americanbankingnews.com logoNabriva Therapeutics AG - (NBRV) Earns "Buy" Rating from HC Wainwright
www.americanbankingnews.com - May 12 at 4:40 PM
finance.yahoo.com logoNabriva Therapeutics Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 10 at 6:57 PM

Social

Chart

Nabriva Therapeutics AG (NBRV) Chart for Monday, August, 21, 2017

This page was last updated on 8/21/2017 by MarketBeat.com Staff